ABSTRACT
La enfermedad de Castleman (ECM) es un desorden linfoproliferativo y con un pronóstico desfavorable, que se lo ha asociado a la infección por el virus herpes humano tipo 8 (HHV-8). El mecanismo supuesto de ac-ción del HHV-8 sería la secreción de interleuquinas (IL) virales, homólo-gas a IL humanas tales como IL-6 e IL-10. La coinfección por HHV-8 y vi-rus Epstein Barr (EBV) es bien conocida en pacientes con infección por el virus de la inmunodeficiencia humana tipo 1 (HIV-1). Estos gamma-herpesvirus se asocian a trastornos linfoproliferativos que son favore-cidos por la inmunosupresión. Puede presentarse en el contexto de un buen estado inmunológico y su tratamiento se basa en el uso de quimioterapia. La reactivación del EBV latente es favorecida por la infección por HIV-1 y el uso de drogas inmunosupresoras, determinando un potencial riesgo para el desarrollo de nuevos desór-denes linfoproliferativos. Se presenta el caso de un paciente con enferme-dad de Castleman asociado a la infección por HIV-1 y HHV-8, que presentó como complicación post-qui-mioterapia reactivación de infección EBV. Se realizó una revisión del concepto de ECM y la relación pato-génica entre los virus HIV-1, HHV-8 y EBV
Castleman's disease (CD) is a lymphoproliferative disorder with an unfavorable prognosis, which has been associated with human herpes virus 8 (HHV-8) infection. The presumed mechanism of action of HHV-8 would be the secretion of viral interleukin (IL), homologous to human IL such as IL-6 and IL-10. The co-HHV8 infection and Epstein Barr virus (EBV) is well known in patients infected with the HIV type 1 (HIV-1). These gamma-herpesvirus were associated with lymphoproliferative disorders that are favored by immunosuppression. It can occur in the context of a patient's good immune system and its treatment is based on the use of chemotherapy. Reactivation of latent EBV is favored by HIV-1 and the use of immunosuppressive drugs, determining a potential risk for the development of new lymphoproliferative disorders.We report here a patient with Castleman's disease associated with HIV-1 and HHV-8, who presented, as a complication of the chemotherapy, the reactivation of EBV infection. A review of the concept of CD and the pathogenic relationship between HIV-1, HHV-8 and EBV virus was performed
Subject(s)
Humans , Male , Middle Aged , HIV Infections/therapy , Castleman Disease/therapy , Herpesvirus 8, Human , Epstein-Barr Virus Infections/therapyABSTRACT
A infecção pelo vírus Epstein-Barr tem alta prevalência, ao passo que 90% da população mundial adulta já teve contato com ele. A primo-infecção geralmente ocorre na infância, apresentando- -se de forma subclínica. Com o avançar da idade, a incidência de infecção sintomática aumenta progressivamente, atingindo o pico entre 15 e 24 anos de idade. Em geral, trata-se de uma doença benigna, na qual a manifestação clínica mais comum é a mononucleose infecciosa. No entanto, a infecção pode acometer qualquer órgão ou sistema, e podem estar presentes tosse, dor abdominal, náuseas, vômitos, hepatoesplenomegalia, icterícia, entre outros. As complicações são raras e podem acometer o fígado, os rins, o sistema nervoso central, o coração, os pulmões e os genitais. Relatamos o caso de paciente adolescente previamente hígido com infecção por vírus Epstein-Barr e evolução para icterícia, pericardite e lesões importantes em orofaringe e genitais. O diagnóstico de infecção pelo Epstein-Barr foi feito por sorologia, e houve boa evolução do caso.
Epstein-Barr virus infection has a high prevalence, since 90% of the adult population worldwide have already had contact with the virus. The primary infection usually occurs in childhood, being subclinically presented. With aging. the incidence of a symptomatic infection progressively increases, reaching the peak between 15 and 24 years of age. In general, it is a benign disease,in which the most common clinical manifestation is Infectious Mononucleosis; however, the infection can occur in any organ or system, and cough, abdominal pain, nausea, vomiting, hepatosplenomegaly, jaundice, and other symptoms may be present. Complications are rare and can affect the liver, kidneys, central nervous system, heart, lungs and genitals. We report the case of a previously healthy adolescent patient with Epstein-Barr Virus infection and progression to jaundice, pericarditis, and important lesions in the oropharynx and genitals. The diagnosis of Epstein-Barr infection was made through serology, and the patient had good evolution.
Subject(s)
Humans , Male , Adolescent , Epstein-Barr Virus Infections/complications , Epstein-Barr Virus Infections/diagnosis , Epstein-Barr Virus Infections/therapy , Herpesvirus 4, Human , Genitalia, Male/injuries , Infectious Mononucleosis , Jaundice , Oropharynx/injuries , PericarditisABSTRACT
Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disease (PTLD) is one of the most serious complications associated with solid organ and hematopoietic stem cell transplantation. PTLD is most frequently seen with primary EBV infection post-transplant, a common scenario for pediatric solid organ recipients. Risk factors for infection or reactivation of EBV following solid organ transplant are stronger immunosuppressive therapy regimens, and being seronegative for receptor. For hematopoietic stem cell transplantation, the risk factors relate to the type of transplant, human leukocyte antigen disparity, the use of stronger immunosuppressants, T-cell depletion, and severe graft-versus-host disease. Mortality is high, and most frequent in patients who develop PTLD in the first six months post-transplant. The primary goal of this article is to provide an overview of the clinical manifestations, diagnosis, accepted therapies, and management of EBV infection in transplant recipients, and to suggest that the adoption of monitoring protocols could contribute to a reduction in related complications.
Subject(s)
Humans , Epstein-Barr Virus Infections , Hematopoietic Stem Cell Transplantation/adverse effects , Lymphoproliferative Disorders/virology , Organ Transplantation/adverse effects , Epstein-Barr Virus Infections/complications , Epstein-Barr Virus Infections/prevention & control , Epstein-Barr Virus Infections/therapy , Immunosuppression Therapy/methods , Immunosuppressive Agents/therapeutic use , Risk FactorsABSTRACT
Se describe un paciente masculino de 10 años de edad con historia de mialgia, debilidad progresiva en miembros inferiores, fiebre y vómitos. Se postuló el diagnóstico clínico de Síndrome de Guillain-Barré el cual fue subsecuentemente demostrado con el resultado de líquido cefalorraquídeo (LCR) y electromiografía. A su admisión se describió una faringoamigdalitis exudativa y una sinusitis etmoidal, y posteriormente durante el curso de su enfermedad desarrolló una parálisis facial derecha. No habia historia de enfermedad diarreica aguada o enfermedad respiratoria previa al inicio de sus síntomas neurológicos. Los frotis y cultivos de heces fueron negativos por Campylobacter jejuni, al igual que la inmunofluorescencia para virus respiratorios y serología por CMV. Se documentó mediante una IgM positiva en suero la infección aguda por el virus Epstein-Barr. El paciente fue tratado exitosamente con un curso de cinco días de gammaglobulina endovenosa y un mes después, en la consulta externa, se documenta la ausencia de secuelas neurológicas